Veradermics, a dermatologist-founded biopharmaceutical company, has reported positive topline results from the female treatment arms of its Phase 2 open-label Study ‘207’ evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in women with mild-to-moderate pattern hair loss.
The study met its primary endpoint. Women treated with a once-daily 30mg dose showed a statistically significant and clinically meaningful improvement in hair growth at 24 weeks, measured by change in nonvellus target area hair count. The results support advancing the female arms into the ongoing Phase 3 program.
VDPHL01 uses extended-release technology built on a gel matrix designed to deliver steady minoxidil release, avoiding the high peak concentrations of immediate-release oral minoxidil while extending time above the minimum hair growth threshold. If approved, it would be the only FDA-approved oral non-hormonal treatment for pattern hair loss in both women and men.
Pattern hair loss affects an estimated 30 million women in the U.S., yet there have been no new FDA-approved prescription medicines for the condition in nearly 30 years. Existing options are limited: topical minoxidil, off-label oral minoxidil, and over-the-counter nutraceuticals that produce inconsistent results. The condition carries a significant psychological burden, with many women experiencing depression, low self-esteem, and social withdrawal – yet it remains under-treated and under-researched.
“These results reinforce our confidence in VDPHL01’s potential to become a foundational treatment for the tens of millions of women living with pattern hair loss,” said founder and CEO Reid Waldman, MD.
The broader pattern hair loss market is projected to reach approximately $30 billion by 2028, making it the largest aesthetics market worldwide. VDPHL01 is currently in Phase 3 development.
